Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

The cost of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) is a substantial economic burden. In Japan, imatinib, dasatinib, and nilotinib are now approved as first-line treatment of CML in chronic phase. Recent stop TKI trials have shown that TKIs can be safely discontinued in nearly one-half of patients with sustained deep molecular response (DMR). In this study, we analyzed the cost-effectiveness of a simulated 10 years of CML treatment including stop TKI in both the United States and Japan. We constructed Markov models to compare 4 strategies in which treatment was initiated with imatinib, dasatinib, nilotinib, or any of these TKIs at the physician's discretion. Treatment was switched to another TKI in the case of intolerance or resistance to the initial TM, and TKIs were discontinued if DMR persisted for 2 years. Imatinib first offered 7.34 quality-adjusted life years (QALYs) at the cost of $1 022 148 in the United States (US dollars) and (sic)32 526 785 in Japan (Japanese yen). In comparison with imatinib first, the incremental cost-effectiveness ratio per QALY of dasatinib first (7.68 QALY, $1 236 052, Y51 506 254), nilotinib first (7.64 QALY, $1 245 667, (sic)39 635 598), and physician's choice (7.55 QALY, $1 167 818, (sic)41187 740) was $641 324, $696 717, and $666 634 in the United States and (sic)54 456 325, Y23 154 465, and (sic)39 635 615 in Japan, respectively. None of the 3 strategies met the willingness-to-pay threshold. The results were robust to univariate and multivariate sensitivity analyses. Imatinib first was shown to be the most cost-effective approach even with the incorporation of stop TKI.